7. Bibliografía
7. Bibliografía
1.
Freije JMP, Diez-Itza I, Balbín M et al.. Molecular Cloning and Expression of Collagenase-3, a Novel Human Matrix Metalloproteinase Produced by Breast Carcinomas. J Biol Chem. 1994; 269: 16766-16773.
2.
Overall CM, López-Otín C.. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Rev Cancer. 2002; 2: 657-672.
3.
Mignatti P, Rifkin DB.. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 1993; 73: 161-195.
4.
López-Otín C, Overall CM.. Protease degradomics, a new challenge for proteomics. Nature Rev Mol Cell Biol. 2002; 3: 509-519.
5.
Woessner JF Jr.. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991; 5: 2145-2154.
6.
Murphy G, Knäuper V, Cowell S et al.. Evaluation of Some Newer Matrix Metalloproteinases. Annals of the New York Academy of Sciences. 1999; 878: 25-39.
7.
Nagase H, Ogata Y, Suzuki K, Enghild JJ, Salvesen G.. Substrate specificities and activation mechanisms of matrix metalloproteinases. Biochem Soc Trans. 1991; 19: 715-718.
8.
Springman EB, Angleton EL, Birkedal-Hansen H, van Wart HE.. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc. Natl. Acad. Sci. U.S.A. 1990; 87: 364-368.
9.
van Wart HE, Birkedal-Hansen H.. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. U.S.A. 1990; 87: 5578-5582.
10.
Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002; 295: 2387-2392.
11.
Egeblad M, Werb Z.. New functions for the matrix metalloproteinases in cancer progression. Nature Rev Cancer. 2002; 2: 163-175.
12.
Noël, V, Fingleton B, Jacobs K et al.. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci. 2001; 114: 111-118.
13.
Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM.. Matrilysin (MMP-7) expression selects for cells with reduced sensitivity to apoptosis. Neoplasia. 2001; 3: 459-468.
14.
Fini ME, Cook JR, Mohan R, Brinckerhoff CE.. En Parks WC, Mecham RP, editors. Matrix Metalloproteinases. Academic Press, Nueva York, 1998; 299-356.
15.
Westermarck J, Kähäri VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999; 13: 781-792.
16.
Kheradmand F, Werner E, Tremble P, Symons M, Werb Z.. Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change. Science. 1998; 280: 898-902.
17.
Simon C, Goepfert H, Boyd D.. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res. 1998; 58: 1135-1139.
18.
Westermarck J, Kähäri VM.. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999; 13: 781-792.
19.
Johansson N, Ala-aho R, Uitto VJ et al.. Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J. Cell Sci. 2000; 113: 227-235.
20.
Ala-aho R, Johansson N, Grenman R, Fusenig NE, López-Otín C, Kahari VM.. Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-? is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1. Oncogene. 2000; 19: 248-257.
21.
Sun Y, Sun Y, Wenger L, Rutter JL, Brinckerhoff CE, Cheung HS.. p53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression. J Biol Chem. 1999; 274: 11535-11540.
22.
Sun Y, Cheung JM, Martel-Pelletier J et al.. Wild-type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem. 2000; 275: 11327-11332.
23.
Morgunova E, Tuuttila A, Bergmann U et al.. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science. 1999; 284: 1667-1670.
24.
Becker JW, Marcy AI, Rokosz LL et al.. Stromelysin-1: three-dimensionalbstructure of the inhibited catalytic domain and of thebC-truncated proenzyme. Protein Sci. 1995; 4: 1966-1976.
25.
Pendás AM, Balbin M, Llano E, Jimenez MG, López-Otín C.. Structural analysis and promoter characterization of the human collagenase-3 gene (MMP13). Genomics. 1997; 40: 222-233.
26.
Knauper V, Will H, Lopez-Otin C et al.. Cellular mechanisms for human collagenase-3 (MMP-13) activation: evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem. 1996; 271: 17124-17131.
27.
Sato H, Takino T, Okada Y et al.. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994; 370: 61-65.
28.
Morrison CJ, Butler GS, Bigg HF, Roberts CR, Soloway PD, Overall CM. Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2 independent pathway. J Biol Chem. 2001; 276: 47402-47410.
29.
Brew K, Dinakarpandian D, Nagase H.. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000; 1477: 267-283.
30.
Khokha R, Waterhouse P, Yagel S et al.. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science. 1989; 243: 947-950.
31.
Oh J, Takahashi R, Kondo S et al.. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell. 2001; 107: 789-800.
32.
Herman MP, Sukhova GK, Kisiel W et al.. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest. 2001; 107: 1117-1126.
33.
Ma Z, Qin H, Benveniste EN.. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-? and IFN-?: critical role of STAT-1?. J Immunol. 2001; 167: 5150-5159.
34.
Lal A, Glazer CA, Martinson HM et al.. Mutant epidermal growth factor receptor upregulates molecular effectors of tumor invasion. Cancer Res. 2002; 62: 3335-3339.
35.
Muraoka RS, Dumont N, Ritter CA et al.. Blockade of TGF-? inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest. 2002:109: 1551-1559.
36.
Shin M, Yan C, Boyd D.. An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta. 2002; 1589: 311-316.
37.
Karin M & Chang L.. AP-1-glucocorticoid receptor crosstalk taken to a higher level. J Endocrinol. 2001; 169: 447-451.
38.
Lund LR, Romer J, Bugge TH et al.. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J. 1999; 18: 4645-4656.
39.
Galvez BG, Matias-Roman S, Albar JP, Sanchez-Madrid F, Arroyo AG.. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J Biol Chem. 2001; 276: 37491-37500.
40.
Annabi B, Lachambre MP, Bousquet-Gagnon N, Page M, Gingras D, Beliveau R.. Green tea polyphenol (-)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells. Biochim Biophys Acta. 2002; 1542: 209-220.
41.
Bassi DE, Lopez De Cicco R, Mahloogi H, Zucker S, Thomas G, Klein-Szanto AJ.. Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci USA. 2001; 98: 10326-10331.
42.
Khatib AM, Siegfried G, Chretien M, Metrakos P, Seidah N.. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol. 2002; 160: 1921-1935.
43.
Kruger A, Fata JE, Khokha R.. Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood. 1997; 90: 1993-2000
44.
Martin DC, Sanchez-Sweatman OH, Ho AT, Inderdeo ES, Tsao MS, Khokha R.. Transgenic TIMP-1 inhibits simian viru s 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis. Lab Invest. 1999; 79: 225-234.
45.
Jiang Y, Goldberg ID, Shi YE.. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002; 21: 2245-2252.
46.
Boissier S, Ferreras M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000; 60: 2949-2954.
47.
Cianfrocca M, Cooley TP, Lee JY et al.. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol. 2002; 20: 153-159.
48.
Duivenvoorden WC, Popovic SV, Lhotak S et al.. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Res. 2002; 62: 1588-1591.
49.
Gu Y, Lee HM, Golub LM, Sorsa T, Konttinen YT, Simon SR.. Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines. Ann Med. 2005; 37:450-460.
50.
Hidalgo M & Eckhardt SG.. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001; 93: 178-193.
© 2010 BioCancer.com